Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

WATSON PHARM : Watson Confirms Court Decision Rejecting Teva's Motion to Prevent Launch of Generic SEASONIQUE®

06/17/2011 | 08:00am US/Eastern

PARSIPPANY, N.J., June 17, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg). The company is evaluating plans to launch the contraceptive product.

On March 25, 2011, Watson received a favorable decision from the United States Court of Appeals for the Federal Circuit that reversed and remanded for trial a March 31, 2010 summary judgment order from the United States District Court for the District of Nevada regarding United States Patent No. 7,320,969 (the '969 patent).

On January 22, 2008, Watson notified Teva Women's Health that Watson's ANDA contained a paragraph IV certification asserting that the '969 patent is invalid, unenforceable and/or not infringed.

SEASONIQUE® is indicated for the prevention of pregnancy.

SEASONIQUE® is a registered trademark of Teva Women's Health, Inc.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)


    CONTACTS:       Investors:
                    Patty Eisenhaur
                    (862) 261-8141

                    Media:
                    Charlie Mayr
                    (862) 261-8030

SOURCE Watson Pharmaceuticals, Inc.

Latest news on ACTAVIS INC
4d ago ACTAVIS : Confirms Generic Quillivant XR® Patent Challenge
10/10 EXCLUSIVE - TOP ACTAVIS HOLDER, FIDE : sources
10/09 Allergan raises outlook; says Valeant offer undervalues company
10/09 ACTAVIS : Ironwood and Actavis to Present Linaclotide Data at the American Colle..
10/07 EXCLUSIVE : Actavis plans new merger approach for Allergan - sources
10/07 EXCLUSIVE - ACTAVIS PLANS NEW MERGER : sources
10/07 ACTAVIS : INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board..
10/07 ACTAVIS : INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Bo..
10/06 Wall St. falls in choppy day; traders wary before earnings
10/06 ACTAVIS : DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. An..
Dynamic quotes  
ON
| OFF